Australia’s Progen, Avexa Agree To Merge, But Shareholders Object
This article was originally published in PharmAsia News
Australian drug makers Progen Pharmaceutical and Avexa have agreed to merge, but some shareholders have stated displeasure with the proposal. Progren has a lot of cash while its liver cancer drug has been struggling in development. Avexa, a biotech, has expertise in oncology and infectious diseases. Avexa also has an HIV antiretroviral, apricitabine, that needs funding to get it into Phase III trials. But shareholders complain the merger would reduce the value of shares of each company. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.